Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE).
Several recently published clinical trials have shown that prophylaxis against postoperative venous thromboembolism with LMWHs is justified on the basis of proven efficacy, safety, better patient acceptability and saving of nursing time. The cost effective analyses also indicate substantial savings can be achieved by using LMWHs, particularly in the high-risk patients. It is believed that emphasis is now on the clinicians who must protect all high-risk patients.
Kakkar
V V
VV
Thrombosis Research Institute, London, UK.
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003911:Dextrans / Q000009:adverse effects / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006493:Heparin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012306:Risk; D012449:Safety; D013924:Thrombophlebitis / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000451:nursing / Q000517:prevention & control*
D000925:Anticoagulants; D003911:Dextrans; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin